Actually, I was just calculating the results for Kintara's drug...

Actually, I was just calculating the results for Kintara's drug for their "head-to-head" trial with Kazia (VAL-083 adjuvant monotherapy), and it seems wrong. I tabulated all patient PFS data for those patients which have already progressed (21 patients) and got the following numbers:

(patient number - approx. PFS in months)
1 - 14.5
2 - 14.2
3 - 11.4
4 - 10.8
5 - 10.5
6 - 10.2
7 - 10
8 - 9.2
9 - 8.6
10 - 8.5
11 - 8.2 <------- median patient
12 - 7.5
13 - 7.2
14 - 6.9
15 - 6.6
16 - 6.3
17 - 5.9
18 - 5.5
19 - 5.5
20 - 5.3
21 - 4.6

From these 21 patients, the median PFS is 8.2 months.

Now, they had 6 other patients which hadn't progressed yet.

1 - 14
2 - 12.2
3 - 10
4 - 9.4
5 - 5.5
6 -4

However, even if we assume they all live to be 100, the median PFS only goes to patient #8 above, which is 9.2 months. If patients #5 and #6 in this bottom set progress sooner than 8.2 months, then the median PFS will be 8.5 months. So, I think the range for mPFS for Kintara should be 8.5-9.2. I don't know how they got 10.